Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract provides no clinical results; it describes terms and navigation options for the JAMA network and its publications.

This study demonstrated that intramuscular corticosteroids were effective for severe alopecia areata, with significant hair regrowth in 80.2% of patients, though a high relapse rate was noted post-treatment. Nail involvement and disease duration over six months negatively impacted outcomes.

This study found that combining excimer light at 308 nm with tacrolimus 0.1% was more effective in treating alopecia areata of the scalp compared to excimer light alone, as indicated by a greater reduction in the SALT score and better improvement in Treg function.

In this study, researchers discovered a compound called C6 that exhibits excellent skin retention and androgen receptor degradation properties, significantly promoting hair regeneration in a mouse model of androgenetic alopecia following non-invasive topical application, suggesting potential for broader use of PROTACs in treating skin diseases.

This study found that lambertianic acid from Platycladus orientalis leaves may protect against dexamethasone-induced skeletal muscle atrophy by reducing atrophy-related proteins without affecting cell viability.

This study identified serum androsterone as a robust biomarker for monitoring response to AKR1C3 inhibitor treatment in women and found that a 4-week administration of aldo-keto reductase 1C3 inhibitors did not impact ovarian function.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This case report highlights a rare instance of diffuse alveolar hemorrhage in a patient with catastrophic antiphospholipid syndrome, emphasizing the importance of early recognition and multidisciplinary management.

In this study, the researchers reported that ischemia-modified albumin and IMA/albumin levels may not effectively predict disease severity in patients with alopecia areata.

Among Australian fur seals at one colony, this study found that alopecia, primarily affecting juvenile females, is linked to hair shaft fractures associated with low tyrosine and zinc levels, as well as higher pollutant exposure.

In this study, researchers observed a significant association between female androgenetic alopecia and coronary artery disease in women under 55, supporting a link similar to that seen in men.

Sebaceous gland maturity and size differ between psoriatic alopecia and alopecia areata.

This study suggests that variations in CAG repeat numbers in the androgen receptor gene may not significantly influence the risk of androgenetic alopecia in Korean males.

In this study, an 11-year-old girl with acrodermatitis enteropathica showed significant improvement in symptoms after oral zinc therapy.

This article discusses the term "androgenetic alopecia" proposed to replace "male pattern alopecia," noting its limited use in American dermatology literature.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.

This study found that systemic ovalbumin–aluminum sensitization followed by cutaneous challenge in mice induced thermal hyperalgesia, increased spinal cord gliosis, and sprouting of nociceptive fibers, along with elevated mast cell and nerve profile densities in the skin compared to controls.

This study found that treating patchy alopecia areata with fractional CO2 laser and topical triamcinolone acetonide was more effective and safer than intralesional triamcinolone, despite higher initial discomfort, as it resulted in greater patient satisfaction and fewer adverse effects like skin atrophy.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This case report describes a unique instance of a 6-year-old girl developing angioedema after treatment with squaric acid dibutylester for alopecia areata.

This study found that in primary cicatricial alopecia, reducing cholesterol production and targeting EMT modulators like PPARγ, AhR, AGTR, and TGFβ with siRNA may help mitigate hair follicle damage by modulating epithelial-mesenchymal transition, suggesting potential therapeutic strategies for slowing PCA progression.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

This study evaluated Korean herbal compounds in silico and identified Biochanin A, Saponin Re, and Emodin as potential topical treatments for androgenetic alopecia, each with specific safety and efficacy considerations.

This study observed a significant association between antigliadin antibodies (IgA and IgG) and alopecia areata severity, suggesting that serological tests could help diagnose subclinical celiac disease in these patients, with IgA and IgG showing 100% sensitivity and specificity at specific cutoff points.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

This study reported that alcoholic cirrhosis patients with zinc deficiency and skin lesions showed rapid symptom improvement with oral zinc sulfate treatment, confirming the diagnosis.

This study identified Saponin Re and Emodin as top candidates for treating androgenetic alopecia, suggesting future research in dermal papilla cell cultures and scalp organoids despite safety concerns.

In this study, in silico analysis identified Saponin Re and Emodin as promising candidates for topical treatment of androgenetic alopecia, with Biochanin A having the most favorable safety profile among the tested compounds.

This study suggests that AKR1C3 expression may influence PGD2-related pathways in skin squamous cell carcinoma and potentially be involved in androgenetic alopecia, although further investigation is needed to clarify its role.